

EI · CML

EUROPEAN INVESTIGATORS ON CML

**25<sup>th</sup> Meeting of the European Investigators  
on Chronic Myeloid Leukemia; EICML,  
Krakōw, March 30<sup>th</sup> - April 1<sup>st</sup>, 2017**



**Meeting chair:** Tomasz Sacha, Aleksander B. Skotnicki

Scientific program



EI · CML

EUROPEAN INVESTIGATORS ON CML

## Meeting Partners

PREMIUM-LEVEL PARTNER



SPONSOR



## Dear Colleagues and Friends,

It is my great honour to host you as guests in Kraków and invite you to participate in the 25<sup>th</sup> European Investigators on CML Meeting. I am very delighted that EICML society have accepted the idea of organization of this very important scientific event for the first time in Poland. Kraków as a former capitol city has an opportunity to present the most valuable monuments belonging to the cultural heritage of the region. I hope that apart from extremely interesting scientific programme created by the participants of the Conference, the social programme will prove to be equally attractive and you will enjoy this Meeting and stay in Kraków.

I wish you a fruitful Meeting and exciting stay in Kraków.

### **Tomasz Sacha**

M.D. Ph.D. Associate Professor,  
Chair and Department of Hematology Jagiellonian  
University Hospital, Kraków, Poland

**Thursday, March 30, 2017**


20.00-22:00 Meeting opening  
- Informal get – together meeting  
(with the industry representatives invited)

**Friday, March 31, 2017**

10.55 – 11.00 Opening of the Conference

11.00 – 12.45 **Special session with pharmaceutical companies**  
**Moderators: A.B. Skotnicki, T. Sacha**

11.00 – 11.20  **Hematology clinical development at Pfizer /**  
**A. Viqueira**

11.25 – 11.45  **Bristol-Myers Squibb**  
**Immunooncology therapies in hematology -**  
**new research directions, new indications /**  
**T. Sacha**

11.50 – 12.00 Coffee Break

12.00 – 12.20  **Targeted Therapy in Late Phase Clinical**  
**Development / F. Watzinger**

12.25 – 13:00  **NOVARTIS**  
**Novartis commitment to TFR / J. Haenig**

13:00– 13.15 Discussion

13.15 – 14.15 Lunch



**14.15 – 16.00 I Scientific session:**

**Biology and immunology of CML / Resistance mechanisms**

**Moderators: J.L. Steegmann, A. Hochhaus**

- Mechanisms of TKI resistance and Disease Progression in Chronic Myeloid Leukemia / **T. Stokłosa**
- Overestimation of TKI-resistance conferred by BCR-ABL1 mutations / **T. Lion**
- Immune response in CML / **A. Burchert**
- Targeting CML stem cells, novel stem cell markers, and NOTCH pathway in CML / **M. Copland**
- Coexistence of JAK2 or CALR mutation is rare but clinically important event in CML patients treated with TKI / **K. Lewandowski**
- Cardio-vascular effects of TKIs / **N. Lazorko**

16.00 - 16.15 Coffee Break

**16.15 – 18.00 II Scientific session:**

**Follow – up of previous proposals / trials updates**

**Moderators: R. Hehlmann, P. Rouselot**

- TIGER and DasaHIT / **A. Hochhaus**
- IFN as a maintenance therapy / **A. Burchert**
- End-results of CML- study IV/ **R. Hehlmann**
- An update of the PETALs trial for CP CML first line / **F. Nicolini**
- EURO-SKI. Final data / **F. X. Mahon**
- CML STOP trials in Russia: inclusion problems and first results / **A. Turkina**
- TFR data obtained in real life on behalf of GIMEMA / **G. Saglio**

18.00 Closure of the first day of Conference



**Saturday, April 1, 2017**

**8.30 – 10.45 III Scientific session:**

**Trials updates II / New drugs / alternative therapy for CML /unmet needs**

**Moderators: G. Saglio, J. Richter**

- SUSTRENIM on behalf of GIMEMA / HOVON/ **F. Pane**
- DASTop2 2nd stop in EuroSKI-patients (Nordics DE, NL, FR)/ **J. Richter**
- Naut Study / **A. Hochhaus**
- MATCHPOINT / **M. Copland**
- DESTINY / **M. Copland, R. Clark**
- Spanish Group experience with Bosutinib / **J. V. Garcia-Gutierrez**
- BosuPeg Randomized BOS+/- RoPegIFN in newly diagnosed CP-CML / **H. Hjorth-Hansen**
- ABL001: How best to continue? The EICML perspective / **A. Hochhaus**

10.45 – 11.00 Coffee Break

**11.00 – 13.15 IV Scientific session:**

**Prognostic factors and scores, statistics, bioinformatics, registries**

**Moderators: M. Baccarani, H. Hjort-Hansen**

- Halving time prognostic value in CML patients treated with TKIs / **W. Prejzner, L. Gorycka**
- Prognostic analyses in CML. Projects and latest activities/ **M. Pfirrmann**
- A European registry of incidence, biology, treatment and outcome of patients in blast crisis/ **M. Lauseker**
- Imatinib generics tolerability – a report from Polish Imatinib Generics (PALG) Registry / **J. Wąclaw, T. Sacha**
- CML and pregnancy: the GIMEMA experience / **E. Abruzzese**
- CML management at pregnancy: Leukemic burden and Term related approach (LET)/ **E. Chelysheva**
- Genotypes predicting imatinib response/ **K. Machova - Polakova**

13.15 – 13.30 Remarks & Closing

13.30 Lunch



EI · CML

EUROPEAN INVESTIGATORS ON CML

EICML  
2017  
KRAKÓW

---

---

ORGANIZER

---



BATUMI Conference & Event Agency Sp. z o. o.  
ul. Marconich 2 lok. 13, 02-954 Warszawa  
tel. + 48 22 885 89 47  
e-mail: [biuro@batumi-agency.pl](mailto:biuro@batumi-agency.pl)  
[www.batumi-agency.pl](http://www.batumi-agency.pl)